Advertisement · 728 × 90

Posts by CholestasisDoc

Post image Post image Post image Post image

Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians

7 months ago 8 2 2 0
Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.

Infographic panel for the Lancet Diabetes & Endocrinology Commission on diagnosing clinical obesity.

🆕 Global Commission proposes overhaul of obesity diagnosis – going beyond BMI to define when obesity is a disease.

Find out more: hubs.li/Q030v_j_0

1 year ago 36 16 2 10
Post image

New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky @oncoalert.bsky.social

1 year ago 9 5 0 2

And why would Mox and Jericho team together?! Surely Mox’s current position makes him against Jericho nonsense?!

1 year ago 2 0 1 0

But the problem is that “why would Hobbs AND Cope be on a match against Mox, if the former were champion? The graphic basically tells viewers that Cope is still going to be gunning for “Mox’s” championship.

1 year ago 0 0 0 0

Because why would Hobbs be in a 12-man with Cope, against Mox, if he was winning the title Wednesday?

The 12-man basically tells the viewer that Mox is gonna face Cope for the championship at the next PPV.

I’d rather be happy than right. So I hope AEW prove me wrong and belt Hobbs tomorrow.

1 year ago 0 0 0 0

Well, not after telegraphing the finish with the god awful 12man planned for Collision next Saturday.

1 year ago 0 0 2 0
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...

Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social

1 year ago 23 10 1 2

New from us: our trial protocol for faecal microbiota transplantation to treat people living with PSC and IBD.

Actively recruiting!
@bhmullish.bsky.social @nabilquraishi.bsky.social @alanmcn1.bsky.social @pscsupport.bsky.social

bmjopen.bmj.com/content/bmjo...

1 year ago 7 2 0 0
Advertisement
Preview
FDA pauses all infant RSV vaccine trials after rise in severe illnesses The US Food and Drug Administration (FDA) has put on hold all respiratory syncytial virus (RSV) vaccine trials involving infants (aged under 2 years) or RSV naive children aged 2-5 years, after a tria...

Agree that mRNA vaccine technology needs deeper evaluation. @fda.gov should provide further details in due course.

www.bmj.com/content/387/...

1 year ago 0 0 0 0
Preview
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV

New work from us:
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.

academic.oup.com/ecco-jcc/adv...

1 year ago 6 2 0 0
Preview
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV

Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky

1 year ago 25 7 0 4